MUC21 and pancreatic adenocarcinoma: In the present study, by analyzing digestive cancer samples from TCGA involving colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), liver hepatocellular carcinoma (LIHC), stomach adenocarcinoma (STAD), and pancreatic adenocarcinoma (PAAD), we found that expression levels of MUC15, MUC13, and MUC21 were individually associated with survival for all these digestive cancers, and high expressions of EMCN (MUC14) and MUC15 were correlated with poor survival for STAD.